Monitoring of plasma concentration changes of specific biomarker TGF beta III soluble receptor in breast cancer patients
| Autor: | Jurišić, Darko |
|---|---|
| Přispěvatelé: | Grgurević, Lovorka, dostupno, nije |
| Jazyk: | chorvatština |
| Rok vydání: | 2023 |
| Předmět: | |
| Popis: | Uvod i cilj istraživanja Karcinom dojke najčešće je maligno oboljenje žena od kojeg obolijeva četvrtina novooboljelih ženskih osoba u svijetu i Hrvatskoj. Cilj ove studije bio je istražiti povezanost molekule TGF β rIII u uzorcima plazme bolesnica s karcinomom dojke i tkiva tumora s prognozom bolesti. Ispitanici i metode U istraživanju su bile uključene 62 bolesnice sa zloćudnim tumorom dojke i 36 zdravih ispitanica u kontrolnoj skupini. ELISA metodom određivali smo koncentraciju TGF β rIII u plazmi bolesnica prije i nakon operativnog zahvata, a imunohistokemijski izražajnost TGFβ rIII proteina u uzorcima tumora dojke. Rezultati U ovom istraživanju po prvi puta smo izmjerili vrijednosti TGF β rIII u plazmi bolesnica s karcinomom dojke te u plazmi zdravih ispitanica. Prosječna koncentracija TGF β rIII u plazmi bolesnica s karcinomom dojke iznosila je 7,63 ng/ml (raspon 14,41 ng/ml), što je bilo značajno niže u odnosu na kontrolnu skupinu (p Background and aim Breast cancer is the most common female cancer disease of which are affected one quarter of women treated for cancer in the world and Croatia. The aim of this study was to explore the relationship of the molecule TGF β rIII in samples of plasma of the patients with breast cancer and tumour tissue with prognosis of the disease. Subjects and Methods The study included 62 female patients with breast cancer and 36 respondents in the control group. ELISA method was used to determine the concentration of the TGF β rIII in the patients' plasma before and after the surgery, while immunohistochemical analysis was used for expression of TGF β rIII protein in breast tumor samples. Results In this research for the first time we measured the values of the TGF β rIII in plasma of the patients with breast cancer and in plasma of healthy respondents. The average concentration of the TGF β rIII in plasma of the patients with breast cancer was 7,63 ng/ml (range 14,41 ng/ml), which was significantly lower concentration compared to the control group (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|